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Abstract: The European Medicines Agency (EMA) is a European
Agency as it is a decentralized body governed by European public
law; it has its own legal personality and is also distinct from the
European Union institutions (Council, Parliament, Commission, etc.).
The EMA presents itself, and is commonly recognised, as a public
health agency. This is notably supported by its recent transition from
the Regional Direction of Research to the Regional Direction of Public
Health. Four recognized principles of public health can be identified as
such: assessment, transparency, precaution and independence. These
principles appear to be closely linked to those forming the basis of
good European governance regarding agencies: efficacy, coherence,
openness, participation and responsibility. Thus, it is interesting to
study how these principles are applied by the EMA in order to assess
the reality of its qualification as a Public Health European Agency.
The principles of assessment and transparency seem to be largely
applied whereas the principles of precaution and independence are
more problematic.
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The European Medicines Agency (EMA) was established by Regulation (EC)
No 726/2004' - in order to "foster scientific excellence in the evaluation and
supervision ofmedicines " to protect and promote public and animal health. It is
a European Agency as it is a decentralized "body governed by European public
law, it is distinct from the European Union institutions (Council, Parliament,
Commission, etc.) and has its own legal personality" as provided by article
71 of Regulation (EC) No 726/2004. It was set up in the context of good
European Governance2 to manage medicinal products at the European Union
(EU) level. Its efficiency has been a method of legitimizing the EU action
in this field, while making patients more confident through safer medicinal
products assessed by the best experts within EU. The basis of good European
Governance is made up of several principles regarding agencies (including the
EMA): efficacy, coherence, openness, participation and responsibility. These
principles can be linked to those of health related safety, and extensively to
public health, as established by Didier Tabuteau: assessment, transparency,
precaution and independence. These principles have been widely recognised
as health safety principles.
Therefore, the EMA is an EU Agency. More specifically, it presents itself,
and it is commonly recognised, as a public health agency due to its missions.
It was created to answer safety questions in the framework of a new safety
governance approach through new connection patterns with Member States
and close interaction with interested parties4.
Regarding these principles and their implementation within the EMA,
one major issue can be raised. That of the difficulty of combining two EU
objectives: to foster competitiveness of European undertakings and guarantee
a high level of protection of human health. Although they are not totally
incompatible, it can be underlined that, most particularly at the EMA level,
1 European Parliament and Council, 2004, Regulation (EC) No 726/2004 laying down
Community procedures for the authorization and supervision of medicinal products for
human and veterinary use and establishing a European Medicines Agency, OJ L 136 of
30/04/2004, p. 1-33.
2 European Commission, 2001, European Governance: a White Paper, COM (2001) 428
final.
3 Tabuteau D., 2002, La sicuritg sanitaire, Ed. Berger-Levrault.
4 Blanquet M. and Valdeyron N., 2010, Le recours A des agences de l'Union en r6ponse aux
questions de s6curit6, Conference organized by l'IRDEIC, 3" Journdes Guy Isaac, Les
Agences de l'Union Europdenne, In press, under the direction of J. Molinier, Ed. Bruylant.
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their conciliation requires a lot of rigour in respect of the aforementioned
principles. If the main task of the EMA is to promote and protect human
and animal health, its actions have a huge impact on the competitiveness of
European pharmaceuticals industries. Moreover, the necessity of enhancing
this competitiveness is strongly and regularly encouraged by EU institutions'.
The difficulty to conciliate these two objectives could be emphasised by the
fact EMA belongs to the Regional Direction of Research at the European
Commission. This could be interpreted as a prioritisation of innovative
institutions and companies in the domain of health rather than the promotion
of health protection as devoted to public health by the European Commission.
However, the EMA is now moving under the responsibility of the Regional
Direction of Public Health directed by Commissioner John Dalli. This
change could mean a shift of priority at the EU level: "While members of
industry are disappointed by the change, health lobby groups point out
that in almost every Member State, policy for medicinal products is
the responsibility of the country health department, and thus expect
that the switch will yield a more 'consistent and coherent'approach to
public health policy "6.
While having to conciliate these two main EU objectives, how does the EMA
apply the Public Health and European Governance principles as a European
Public Health Agency?
The aim of this study is to emphasize how the EMA implements these
principles. On the one hand, principles of assessment and transparency which
could correspond to efficacy, coherence, openness and participation in the
context of good governance seem to be largely applied (1). On the other hand,
principles of precaution, independence and responsibility appear to be more
problematic (2).
1. ASSESSMENT AND TRANSPARENCY: THE EMA
"WINNING COMBINATION"
The principle of assessment and the principle of transparency are those which
are the most visibly applied by the EMA. Even though the protection of
5 European Commission, 2008, Communication to the European Parliament, the Council,
the European Economic and Social Committee and the Committee of the Regions - Safe,
Innovative and Accessible Medicines: a Renewed Vision for the Pharmaceutical Sector,
COM/2008/0666 final.
6 OrphaNews Europe, 2009, Newsletter of the Rare Disease Task Force, EU Policy News.
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human health and the promotion of undertaking competitiveness could imply
opposite actions on the part of the EMA, it is recognised as managing well,
and even enhancing, its capacity to implement these two principles.
1.1 The Recognition of the EMA Assessment's High Quality
The quality of the assessment provided by the EMA appears from a
substantive as well as an organisational point of view. In this context, the
principle of assessment rejoins the principles of effectiveness and coherence
of European governance. Indeed, it can be considered that the principle of
assessment, or "good assessment", requires the efficiency, the effectiveness
and the coherence of the system according to the main objectives of EMA,
i.e. the protection and promotion of human and animal health. According to
the European Commission, the principle of effectiveness means that "policies
must be effective and timely, delivering what is needed on the basis of clear
objectives, an evaluation of future impact and, where available, of past
experience ". It also requires implementation of EU policies in a proportionate
manner and taking decisions at the most appropriate level'. Moreover, the
principle of coherence is achieved where policies and actions are "coherent
and easily understood". "Coherence requires political leadership and a strong
responsibility on the part of the Institutions to ensure a consistent approach
within a complex system "'.
The assessment of the EMA is required through several processes which are
also the EMA tasks and the reason for its creation. The high quality of its
assessment is fostered by the qualification of its experts and the setting up of
specialised committees and working groups which interact.
Without being exhaustive, the main EMA tasks of assessment will be
considered.
Firstly, the EMA scientifically assesses human and animal medicinal products
for marketing authorisation through a centralised procedure. According to this
procedure, companies submit a single marketing authorisation application
to the EMA. Once granted by the European Commission, after the EMA's
assessment on the basic requirements of quality, safety and efficacy, the
authorised medicinal products can be marketed in the entire European Union
7 European Commission, 2001, European Governance: a White Paper, COM (2001) 428
final.
8 Cf. Supra European Commission, 2001
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and in EEA-EFTA States. Medicinal products, which have to be approved via
the centralised procedure are mainly the following: all medicinal products for
human and animal use derived from biotechnology and other high technology
processes; all human medicines intended for the treatment of HIV/AIDS,
cancer, diabetes, neurodegenerative diseases, auto-immune and other immune
dysfunctions, and viral diseases; all designated orphan medicines intended
for the treatment of rare diseases; all veterinary medicines intended for use
as performance enhancers in order to promote the growth of treated animals
or to increase yields from treated animals. Moreover, companies can submit a
marketing authorisation application to the EMA where the medicinal product
constitutes a significant therapeutic, scientific or technical innovation, or the
product is in any other respect in the interest of patient or animal health.
The main Committees involved in the scientific assessment of medicinal
products are the Committee for Medicinal Products for Human Use (CHMP)
and the Committee for Medicinal Products for Veterinary Use (CVMP) 0 .
However, other more specialised Committees have been established by EU
Regulations and concretely set up by the EMA: the Committee for Orphan
Medicinal Products (COMP)", the Committee on Herbal Medicinal Products
(HMPC)12, the Paediatric Committee (PDCO)'3 and the Committee for
Advanced Therapies (CAT)14. These committees have then been concretely set
up by the EMA in accordance with their foundation's regulations. Moreover,
9 EMA, 2007, Committee for Medicinal Products for Human Use, rules of procedures,
EMEA/ 45110/2007, EMEA/MB/87146/2007.
10 EMA, 2007, Committee for Medicinal Products for Veterinary Use, EMEA/CVMP/422/04-
Rev. 1, EMEA/MB/47098/2007.
11 European Parliament and Council, 1999, Regulation (EC) No 141/2000 on orphan
medicinal products, OJ L 18 of 22/01/2000, p. 1-5.
12 European Parliament and Council, 2004, Regulation (EC) No 726/2004 laying down
Community procedures for the authorization and supervision of medicinal products for
human and veterinary use and establishing a European Medicines Agency, OJ L 136 of
30/04/2004, p. 1-33 and European Parliament and Council, 2004, Directive 2004/24/EC
amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the
Community code relating to medicinal products for human use, OJ L 136 of 30/04/2004,
p. 85-90.
13 European Parliament and Council, 2006, Regulation (EC) No 1901/2006 on medicinal
products for paediatric use and amending Regulation (EEC)No 1768/92, Directive 2001/20/
EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, OJ L 378 of 27/12/2006, p.
1-19.
14 European Parliament and Council, 2007, Regulation (EC) No1394/2007on advanced
therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC)
No726/2004 OJ L324, 10/12/2007, p.121-137
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several standing and temporary Working Parties (WP) have been established
by the EMA' s Committees15 to get high quality scientific and regulatory input
in a number of areas based on growing and new scientific needs. Given a rise in
the creation of new committees and the increase of complexity and workload
of the system, the EMA decided to reorganise the structure, composition
and mandate of CHMP WPs in order to improve their efficiency and avoid
overlapping and unnecessary competition among them. This reorganisation
took effect in September 2010 and was published on the EMA's website on the
2 5th of October 2010. The main changes were: the "replacement ofthe Efficacy
Working Party with a number of temporary working parties with narrower
fields of expertise; the establishment of drafting groups to draw up and review
guidelines that do not fall within the remit of existing working parties; the
establishment of a Co-ordination Group to co- ordinate the activities of the
working parties and drafting groups"I'. Therefore, two main types of WPs
have been identified. On the one hand, standing WPs (i.e. Biologicals, Safety
and Quality WPs) with transversal competences are "responsible for keeping
a regular ongoing activity in their respective fields as per their mandate" .
On the other hand, temporay WPs with more specific competences linked
to a particular therapeutic class or kind of products are convened to deliver
guidelines or address issues in a concrete and specific task over a defined
timeline". Moreover, the CHMP/CVMP can create specific ad hoc Drafting
Groups which deal with very particular and short term mattersl 9. Next to the
WPs which are mainly composed of experts belonging to national agencies,
the CHMP/CVMP establish scientific advisory groups (SAGs) which consist
of European independent experts to answer specific questions related to the
evaluation of particular types of medicines or treatments. Committees can
also be supported by committee-associated groups providing expertise in
15 In accordance with Article 56 (2) of Regulation (EC) no 726/2004, cf. supra.
16 EMA, 2010, News, CHMP working parties reorganized: http://www.ema.europa.eu/
ema/index.isp?curl=pages/news and events/news/2010/10/news detail 001137.
jsp&murl=menus/news and events/news and events.isp&mid=WCObO1acO58004d5cl
17 EMA, 2010, Reflection paper on working parties (WP) CHMP/EMA group analysis and
proposals, EMA/315270/2010.
18 According to the implementation plan, the final distribution of temporary WPs is as
follows: Blood Products, Biosimilar, Vaccines, Pharmacogenomics, Pharmacokinetics,
Biostatistics, Cardiovascular, Central Nervous System, Infectious diseases, Oncology
Working Parties. Cf. supra EMA, 2010, Reflection paper on working parties.
19 According to the implementation plan, the final distribution of Drafting Groups is as
follows: Endocrinology, Rheumatology/Immunology, Respiratory, Gastroenterology
Drafting Groups. Cf. supra EMA, 2010, Reflection paper on working parties.
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their respective areas20. Finally, the CHMP has established other groups: a
Co-ordination Group to ensure integrated management of the operation of the
scientific committees, WPs and Drafting Groups2 1, and a Consistency Group
which conducts peer reviews of all draft guidelines before they are discussed
at the CHMP in order to maintain regulatory and scientific consistency.
The EMA is also involved in referral procedures related to medicinal products
approved by Member States through the mutual-recognition procedure22
and the decentralised procedure23 . In accordance with those procedures, the
Co-ordination Group for Mutual Recognition & Decentralised Procedures-
Human (CMD(h)) 24 and the Co-ordination Group for Mutual Recognition &
Decentralized Procedures -Veterinary (CMD(v))25 were set up to examine any
question relating to marketing authorization of a medicinal product in two or
more Member States. They hold their monthly meetings at the EMA which is
responsible for their secretariat.
Secondly, the EMA constantly monitors the safety of medicinal products
through a pharmacovigilance network. In 1995, a Pharmacovigilance Working
Party26 was established to provide advice to the CHMP on any scientific
issues directly or indirectly related to pharmacovigilance for medicinal
products submitted for centralized marketing authorisation. It also provides
20 Healthcare Professionals' Working Group, (Invented) Name Review Group, Working
Group on quality Review of Documents.
21 EMA, Co-ordination Group: http://www.ema.europa.eu/ema/index.isp?curl=pazes/
contacts/CHMP/people listing 000080.isp&murl=menus/about us/about us.j sp&mid=
WCObOlacO5802327cf&jsenabled-true
22 The mutual recognition procedure is "compulsory for all medicinal products to be
marketed in a Member State other than that in which they were first authorized". For more
information on this procedure, see the European Commission's website, Public health,
The Mutual Recognition Procedure: http://ec.europa.eu/health/authorisation-procedures-
mutual-recognition en.htm
23 As the mutual recognition procedure, the decentralized procedure "is also based on
recognition by national authorities of a first assessment performed by one Member
State. The difference lies in that it applies to medicinal products which have not received
a marketing authorization at the time of application". For more information on this
procedure, see the European Commission's website, Public health, The Decentralized
Procedure: http://ec.europa.eu/health/authorisation-procedures-decentralised en.htm
24 Co-ordination Group for Mutual Recognition and Decentralized Procedures- Human:
http://www.hma.eu/cmdh.html
25 Co-ordination Group for Mutual Recognition and Decentralized Procedures- Veterinary:
http://www.hma.eu/cmdv.html




recommendations for non-centrally authorized products upon request of
national competent authorities.
Thirdly, the EMA promotes innovation and research in the pharmaceutical
sector by giving scientific advice and protocol assistance to companies for
the development of new medicinal products. It adopts guidelines on quality,
safety and efficacy requirements and on European processes for centrally-
authorised medicinal products. A specific assistance is also provided for small
and medium-sized enterprises.
For each process, relevant Committees, Working Parties and Scientific
Advisory Groups are involved. Their members are nominated for their high
qualification and experience in the considered matters.
One of the difficulties of the EMA is that its assessments should attain a high
level of scientific quality and rigour, despite the fact, for instance, that a refusal
for marketing authorisation would imply slowing down the competitiveness
of the applying undertaking. The numerous exchanges between the EMA and
the applicants aim to avoid such negative opinions.
The European Commission Evaluation of the EMA ascertains that the
organisation system of the EMA (being defined as the combination of EMA
Secretariat and the contribution of 44 National Competent authorities) is
recognised as being very effective by all stakeholders, i.e. pharmaceutical
companies, healthcare professionals and patient and consumer organisations.
Indeed, it is especially noticed that the "best available experts in Europe "
contribute to the assessments for centralised authorisation of human and
veterinary medicinal products. In addition, "the European authorisation
system provides complete, clear and highly valued opinions within regulatory
tight deadlines" even if the EMA workload has been enhanced27 . However,
the chosen system with numerous different committees and groups within
the EMA appeared to complicate attaining a quality assessment as all the
procedures between these groups have to be validated and efficient. That is
why it has been reorganized as explained above.
1.2 The Improvement of the EMA Level of Transparency
The principle of transparency can be linked to the principles of openness
27 European Commission, 2010, Evaluation of the European Medicines Agency, Final Report,
Evaluation conducted by Ernst & Young et Associds.
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and participation of European governance. On the one hand, the principle
of openness means: "The Institutions should work in a more open manner
Together with the Member States, they should actively communicate about
what the EU does and the decisions it takes. They should use language that
is accessible and understandable for the general public. This is ofparticular
importance in order to improve the confidence in complex situations"28. On
the other hand, according to the participation principle, "the quality, relevance
and effectiveness of EU policies depend on ensuring wide participation
throughout the policy claim - from conception to implementation. Improved
participation is likely to create more confidence in the end result and in
the Institutions which deliver policies. Participation crucially depends on
central governments following an inclusive approach when developing and
implementing EU policies "29.
From its creation, and according to article 80 of the Regulation (EC) No
726/2004, the Management Board of the EMA shall ensure an appropriate
level of transparency with the adoption of rules providing "the availability
to the public of regulatory, scientic or technical information concerning
the authorisation or supervision of medicinal products which is not of a
confidential nature ". This has notably been ensured through the development
of the EMA's website and the numerous public consultations.
However, due to increasing stakeholders' expectations and the European
Ombudsman's recommendation to increase transparency (it was drafted
following a complaint by an Irish citizen in 2008 as the EMA had refused
a request to access individual adverse drug reaction reports for a nationally
authorised medicine used to treat acne)30, the EMA is developing a wide
transparency policy.
In this context, one can refer to the main recent activities of the EMA to
improve its level of transparency.
On 19 June 2009, EMA launched a public consultation process on a new
transparency policy intended to provide for greater clarity and openness in all
its operations. The three main objectives of this policy are the following: "to
28 Cf. Supra European Commission, 2001.
29 Cf. Supra European Commission, 2001.
30 European Ombudsman, P. Nikiforos Diamandouros, 2010, Draft recommendation of




apply a more proactive approach to transparency in the daily operations of the
Agency ", "to further strengthen interaction with the Agency ' stakeholders ",
and "to promote cooperation transparency issues within the European
medicines network"". The EMA also organised two workshops on the
development of an Agency's Transparency Policy on 22 January 2009 and on
19 October 2009 where members from patients', consumers' and healthcare
professionals' organisations and learned societies, and farmers' unions were
invited.
Moreover, the EMA opened public consultations such as on the EMA's
draft Eudravigilance access policies in relation to human and veterinary
medicines32. Following its public consultation on the EMA's draft policy on
access to documents", it widens public access to documents through its new
policy on this subject3 4, adopted at the end of November 2010.
The EMA also published a report on patients', consumers' and healthcare
professionals' expectations concerning information on the benefit-risk
balance of medicines and initiated a study on its benefit-risk communication
activities".
Finally, it can be noted that the EMA has a new visual identity since the 8k" of
December 2008, notably through a new motto, "to communicate to the public
a clearer message about its role and activities ". It has also developed a new
website "providing better access to information on public health issues" and
its members also published articles in scientific journals36.
Although the EMA's respect of principles of assessment and transparency
is widely recognised, through its regular and increasing efforts, the
implementation by this Agency of principles of precaution and independence
31 EMA, 2009, The EMA Transparency Policy, Draft for public consultation, London,
EMEA/232037/2009-rev
32 EMA, 2008, Draft, Eudravigilance access policy for medicines for human use, London,
EMEA/1 87439/2006/Final.
33 EMA, 2008, Draft, EMEA Policy on the practical operation of access to EMEA documents,
London, EMEA/1 101 96/2006/Final.
34 EMA, 2010, European Medicines Agency policy on access to documents (related to
medicinal products for human and veterinary use), London, EMA/110196/2006.
35 EMA, 2009, Information on benefit-risk of medicines: patients', consumers' and healthcare
professionals' expectations, London, EMEA/40926/2009.
36 EMA, 2010, Annual Report 2009 adopted by the Management Board, EMA/
MB/69923/2010.
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has to be considered in another context. Consequently it becomes more
arguable.
2. PRECAUTION AND INDEPENDENCE: AN ARGUABLE
SITUATION FOR THE EMA
The EMA implementation of principles of precaution and independence
reveals an arguable situation as long as it does not depend on the internal
organisation of the EMA. Indeed it rather relies on its relations with relevant
actors such as the European Institutions, Member States" and European
Pharmaceutical companies.
2.1 The "Secondary"Role of the EMA for the Principle of Precaution
Implementation
"The precautionary principle has been politically accepted as a risk
management strategy in several fields"I' including notably the protection
of human and animal health. According to the European Commission, the
structured approach of the analysis of risk comprises three elements: risk
assessment, risk management, risk communication.
In the context of EU central marketing authorisation, risk assessment and risk
communication are tasks of the EMA whereas risk management where the
implementation of the precautionary principle is particularly relevant would
mainly be the task of the European Commission.
Thus, there is a sharing of competencies between the European Commission
and the EMA regarding risks. On the one hand, the EMA scientifically
assesses medicinal products regarding quality, safety and efficacy criteria. It
compares the benefits and risks of the medicinal products to be placed on the
market. Where EMA identifies potentially dangerous effects deriving from a
product, it shall, where possible, identify the degree of scientific uncertainty at
each stage. On the other hand, regarding scientific uncertainty, the European
Commission, which is the decision-maker, has the responsibility to choose
whether or not to authorise a medicinal product by judging the "acceptable"
level of risk for society. Its action measures should be, inter alia: proportional
37 Saurugger S., 2009, Thdories et concepts de l'int6gration europ6enne, Paris, Presses de
Sciences Po.
38 European Commission, 2000, Communication on the precautionary principle, COM
(2000) 1 final.
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to the chosen level of protection, non-discriminatory in their application,
consistent with similar measures already taken, based on an examination of
the potential benefits and costs of action or lack of action, subject to review
and capable of assigning responsibility for producing the scientific evidence
necessary for a more comprehensive risk assessment.
Thus, according to the European Commission, the precautionary principle
has two aspects: the decision to act and the manner to act which are both a
European Commission's prerogative.
It could be thought that the EMA also applies the precautionary principle
through its benefits/risks scientific assessment. However, the European
Commission has specified the difference between a prudential approach
and the application of the precautionary principle which are complementary
aspects. They should not be confounded as "the prudential approach is part
ofrisk assessment policy which is determined before any risk assessment takes
place [...J, it is therefore an integral part of the scientific opinion delivered by
the risks evaluators ".
But this theoretical distinction could appear confusing in practice and would
necessitate a study of the EMA assessments.
2.2 The Limited Independence of the EMA
The principle of independence can be linked to the principle of accountability
of the European governance. According to the White Paper on European
governance, accountability implies that "roles in the legislative and executive
processes need to be clearer Each of the EU Institutions must explain and
take responsibility for what it does in Europe. But there is also a need for
greater clarity and responsibility from Member States and all those involved
in developing and implementing EU policy at whatever level ".
The term "accountability" is often assimilated into the notion of "control" and
the notion of "independence" has been used as identical to that of "formal
institutional separation" whereas these notions are interrelated and should not
be considered identical3 9.
For this study, the two dimensions of independence provided by Pollitt et al.
39 Busuioc M., 2009, "Accountability, Control and independence: the case of European
Agencies", European Law Journal, Vol. 15, No5, pp. 599-615.
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shall be considered: on the one hand, separation or disaggregation means the
degree to which an organisation is institutionally separated from the parent
body, and on the other hand, autonomisation entails discretion and autonomy
in decision-making 0 . However, to be complete, a third dimension to the notion
of independence should be added: its separation and autonomy from Member
States and from companies which 'benefit' from its services.
Firstly, regarding the European Commission, the level of independence of the
EMA appears almost non existent. Two members of the EMA's management
board are representatives of the European Commission. According to the
Committee considered, the European Commission can be represented (for
instance, it is the case at the COMP), or it participates in the nomination of
representatives of patients associations and health professionals. In any cases,
representatives of the European Commission may attend all meetings of the
EMA's Committees, their working parties and their scientific advisory groups.
The influence of the European Commission shall not be underestimated as
long as it plays an important role regarding the financial contribution of the
EU to the EMA. For instance, it enters what deems necessary in the estimate
of revenue and expenditure of the EMA for the following year established
by the Management Board. Then it forwards it to the budgetary authority,
i.e. the European Parliament and the Council for adoption. Thus, when the
representatives of the European Commission give a warning on a particular
scheme they do not want to give money for, it is often not pursued41. On the
other hand, the EMA does not have real discretion and autonomy in decision-
making, in so far as, for instance, when granting marketing authorisation, the
EMA's Committees only provide opinions and the final decision is adopted by
the European Commission. However, it seems that opinions of the EMA are
most of the time supported by the European Commission. Therefore, what is
the real value of the lack of EMA's legal autonomy for decision-making if it
has it in practice?
Secondly, regarding the European Parliament and the Council, as budgetary
authority, they have a direct influence on the actions to be undertaken by the
EMA when adopting its establishment plan and authorising appropriations
for the subsidy to the EMA. Moreover, two representatives of the European
Parliament are members of the Management Board. The European Parliament
40 Pollitt C. et al., 2004, "Agencies. How governments do things through semi-autonomous




is also consulted by the European Commission when appointed members of
the PDCO and the CAT who represent healthcare professionals and patients
associations.
Thirdly, Member States are very well represented at the EMA. Representatives
and alternates of each Member State are members of the Management Board
and of the six EMA's Committees42.
Fourthly, the EMA's link with pharmaceutical industries is particular as the
EMA's revenue also consists of fees paid for undertaking the services it
provides. It represents more than 70% of the EMA's revenue43. Can we really
consider that the EMA is independent from these companies? Furthermore,
especially when there are only few competent experts in a specific area,
the evaluated industry, the external expert and the members of the EMA's
Committee often know each other. Thus, the question of the degree of
impartiality around a procedure can be raised. The conflicts of interest are
envisaged at the EMA through declarations and specific procedures within
each committee. However, the links and influences of the pharmaceuticals
industries on EMA's experts is a much more complex issue. If the numerous
exchanges between pharmaceuticals industries and EMA's experts are always
a source of influence risks, they could also contribute to the adoption of
opinions which further guarantee the protection of human health".
CONCLUSION
Even though the EMA is commonly recognised as a European Public Health
Agency, its way of implementing principles of public health and principles
of European governance make it a particular Agency. While its efforts
concerning the respect of principles of assessment and transparency and
its continuous improvements are widely appreciated, its implementation of
precaution and independence has to be considered in a particular context. On
the one hand, precaution is a Commission's prerogative. On the other hand,
42 Urfalino P. et Hauray B., 2007, "Expertise scientifique et intirats nationaux. L'6valuation
europdenne des mdicaments 1965-2000", Annales. Histoire, Sciences Sociales 2007/2,
62e annie, p. 273-298.
43 European Commission, 2010, Evaluation of the European Medicines Agency, Final Report,
Evaluation conducted by Ernst & Young et Associds.
44 Greene J., 2007, "Prescribing By Numbers: Drugs and the Definition of Disease",
Baltimore, Johns Hopkins University Press.
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the EMA could not be considered as an independent agency. Regarding the
European Institutions and Member States, the dependence of the EMA relies
on a governance choice. However, concerning European pharmaceutical
companies, the EMA should be independent. The assessment of the real degree
of autonomy of the EMA concerning European pharmaceutical undertakings
requires further studies.
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POSEIDON GA 2006210: http://www.poseidon-hsct.eu/index.php
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